7 October 2024 India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative.
Swiss pharma giant Novartis yesterday announced that the US District Court for the District of Delaware issued a negative decision regarding the validity of a patent covering its heart failure treatment Entresto and combinations of sacubitril and valsartan, which expires in 2025 with its pediatric exclusivity. 8 July 2023
Danish pharma and medical equipment maker Coloplast on Friday revealed it has entered into an agreement to acquire Kerecis, an Iceland based developer of biologics for the wound care market, using. fish skin to develop tissue-transplant products. 8 July 2023
A positive scientific opinion has been issued under the UK’s Early Access to Medicines Scheme (EAMS) for Jemperli (dostarlimab) alongside platinum-containing chemotherapy for mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer patients who are candidates for systemic therapy. 7 July 2023
The US Department of Health and Human Services (HHS) today announced actions to protect consumers from junk health plans, surprise medical bills, and excess costs that lead to medical debt. 7 July 2023
The US Food and Drug Administration (FDA) has removed the partial clinical hold on the TakeAim Leukemia Phase I/II study of emavusertib for the treatment of hematologic malignancies, conducted by US biotech Curis. 7 July 2023
The US Food and Drug Administration (FDA) has converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer's Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit. 7 July 2023
Spanish skincare specialist Almirall has announced positive results from a real-world study of Ilumetri (tildrakizumab) at the 25th World Congress of Dermatology. 7 July 2023
Indian drugmaker Biocon says that its subsidiary Biocon Biologics has completed the integration of the acquired biosimilars business in over 70 countries in emerging markets effective July 1, 2023, ahead of schedule, increasing the scale and scope of its business. 7 July 2023
Privately-held Italian drugmaker Chiesi Farmaceutici has appointed Alessandro Chiesi as chairman of the Chiesi Group. Additionally, it said that Maria Paola Chiesi becomes vice chair. 7 July 2023
New Jersey, USA-based oncology company Hillstream BioPharma has signed an exclusive collaboration agreement with the Applied Biomedical Science Institute (ABSI). 7 July 2023
Shares of US clinical-stage drug developer Histogen rocketed 33% to $$0.97 in after-hours trading yesterday, after it indicated that the company could be up for sale. 7 July 2023
Shares in Singapore and California-based biotech ASLAN Pharmaceuticals have fallen by a quarter as traders pore over mid-stage data for lead candidate eblasakimab. 7 July 2023
The European Medicines Agency (EMA), the European Commission (EC) and the Heads of Medicines Agencies (HMA) are phasing out the extraordinary regulatory flexibilities for medicines put in place during the COVID-19 pandemic to help address regulatory and supply challenges arising from the pandemic. 7 July 2023
Wuppertal, Germany-based infectious disease drug developer AiCuris Anti-infective Cures today announced that it has sharpened its strategic focus on the development of novel, therapeutic candidates for the prevention and treatment of moderate to severe and 6 July 2023
The UK-based non-profit medical research organization and charity LifeArc has announced a program to invest more than £100 million ($127 million) by 2030 to deliver new breakthroughs in rare diseases. 6 July 2023
Shorla Oncology, a privately-held, female founded US-Ireland pharmaceutical company, today announced it has entered into a licensing agreement and strategic partnership with a UK-based innovative drug development and manufacturing company. 6 July 2023
Eisai has broken new ground in the development of Alzheimer's treatments, gaining the first approval for decades. In the runup to AAIC 2023, we discuss progress with the deputy chief clinical officer of the firm's American business. 6 July 2023
Israel-based Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia (denosumab). 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an overview of the efficacy and safety of twice-yearly lenacapavir. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
UK-based ViiV Healthcare, the specialist HIV company majority-owned by GSK (LSE: GSK), with Pfizer and Shionogi as shareholders, has announced a milestone in its efforts to achieve widespread international access to its therapies. 7 October 2024
Texas Attorney General Ken Paxton has filed a lawsuit against major pharmaceutical companies, including Eli Lilly (NYSE: LLY), alleging a conspiracy to artificially inflate the prices of insulin by up to 1,000%. 7 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024
AstraZeneca’s (Airsupra (albuterol/budesonide) has met the primary endpoint of a Phase III trial, showing a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol. 7 October 2024
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024